Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 10/20 | 0.37 |
| ▸ | GSK3B | P49841 | 9/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 9/20 | 0.36 |
| ▸ | PRKACA | P17612 | 9/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 9/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 9/20 | 0.36 |
| ▸ | MELK | Q14680 | 8/20 | 0.36 |
| ▸ | CDK8 | P49336 | 8/20 | 0.36 |
| ▸ | PAK4 | O96013 | 8/20 | 0.36 |
| ▸ | CDK2 | P24941 | 8/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837771 | 0.87 | CDC7 (0.39) | KMT2AMAPTCDC7GSK3BSMN1; SMN2 | |
| SCHEMBL17837386 | 0.83 | AXL (0.40) | MAPTAXL | |
| SCHEMBL17837993 | 0.78 | AXL (0.53) | AXL | |
| SCHEMBL17837874 | 0.77 | AXL (0.52) | KMT2ACDC7GSK3BDAPK3PRKACA | |
| SCHEMBL17837617 | 0.76 | AXL (0.42) | AXL | |
| SCHEMBL17837534 | 0.76 | AXL (0.45) | AXL | |
| SCHEMBL21733021 | 0.71 | PDK2 (0.47) | CDC7GSK3BDAPK3PRKACAMINK1 | |
| SCHEMBL31451916 | 0.71 | KMT2A (0.71) | KMT2AMAPTKDM4ERXFP1SMN1; SMN2 | |
| SCHEMBL17837953 | 0.70 | AXL (0.54) | AXL | |
| SCHEMBL17524924 | 0.70 | DRD4 (0.38) | KMT2ALMNAMAPK1RETCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3233829-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | Pfizer Inc (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176850-A1 | AXL INHIBITORS | AXL, FLT3, MERTK | KMT2A 2202/4885MAPT 1834/4885KDM4E 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.